
Inhaled Imatinib, AV-101, Tolerated Well at All Doses in Phase 1 Trial
Aerovate Therapeutics‘ AV-101, an inhaled formulation of imatinib for treating pulmonary arterial hypertension (PAH), was well tolerated in healthy adult volunteers enrolled in a Phase 1 trial. Study data also indicate AV-101, which delivers the medication directly…